Telix Pharmaceuticals (NASDAQ:TLX) Cut to “Sell” at Wall Street Zen

Telix Pharmaceuticals (NASDAQ:TLX) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday.

A number of other brokerages have also recently weighed in on TLX. Wedbush restated an “outperform” rating and issued a $22.00 price objective on shares of Telix Pharmaceuticals in a research note on Thursday, August 28th. Weiss Ratings reiterated a “sell (d)” rating on shares of Telix Pharmaceuticals in a report on Wednesday, October 8th. Canaccord Genuity Group raised shares of Telix Pharmaceuticals to a “strong-buy” rating in a research report on Monday, October 6th. UBS Group lowered their price target on Telix Pharmaceuticals from $23.00 to $20.00 and set a “buy” rating on the stock in a research report on Tuesday, September 23rd. Finally, HC Wainwright dropped their price objective on Telix Pharmaceuticals from $23.00 to $20.00 and set a “buy” rating on the stock in a research note on Wednesday, September 10th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $21.00.

Telix Pharmaceuticals Price Performance

Shares of TLX stock opened at $7.80 on Friday. The stock’s 50 day simple moving average is $9.79 and its 200 day simple moving average is $11.91. Telix Pharmaceuticals has a twelve month low of $7.72 and a twelve month high of $30.36.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in TLX. Millennium Management LLC bought a new stake in shares of Telix Pharmaceuticals in the third quarter valued at about $1,883,000. Pier Capital LLC acquired a new position in Telix Pharmaceuticals in the 2nd quarter valued at approximately $3,037,000. Portland Investment Counsel Inc. bought a new stake in shares of Telix Pharmaceuticals in the 3rd quarter worth approximately $1,225,000. Lazard Asset Management LLC bought a new stake in shares of Telix Pharmaceuticals in the 3rd quarter worth approximately $1,097,000. Finally, Russell Investments Group Ltd. acquired a new stake in shares of Telix Pharmaceuticals during the 2nd quarter worth approximately $975,000.

Telix Pharmaceuticals News Summary

Here are the key news stories impacting Telix Pharmaceuticals this week:

• Positive Sentiment: Advancement of TLX591 into ProstACT Global Phase 3 Part 2 — a clinical development milestone that supports the company’s long-term commercial case for its prostate cancer program. Telix valuation/clinical update
• Neutral Sentiment: Recent analyst coverage is cautious: RBC initiated coverage with a Sector Perform rating and a price target that implies upside vs current U.S. quotes, but the note emphasizes a cautious commercial outlook and execution risk. InsiderMonkey summary
• Negative Sentiment: Hagens Berman highlights serious allegations including an SEC subpoena and an FDA complete response letter (CRL) focused on CMC/supply‑chain and third‑party manufacturing deficiencies tied to TLX591, and urges investors to act by Jan. 9 — these specific regulatory and oversight claims raise material execution and disclosure risk. Hagens Berman PR
• Negative Sentiment: Multiple shareholder‑rights firms (Berger Montague, Faruqi & Faruqi, Levi & Korsinsky, Rosen, The Gross Law Firm, Schall, et al.) have filed or circulated class‑action notices and reminders relating to securities purchased Feb. 21–Aug. 28, 2025 and the Jan. 9 lead‑plaintiff deadline — the wave of litigation notices increases headline risk, potential litigation costs and market volatility. Berger Montague notice

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.